Compare Lemonade Inc (LMND) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lemonade Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Lemonade Inc trades at $43.49 (market cap $3.46B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Lemonade Inc is far larger — about 3.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lemonade Inc for 27 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LMND | MRVI | |
|---|---|---|
Market Cap | $3.46B | $972.90M |
Volume | 1,011,472 | 4,325,710 |
Sector | Financials | Health |
52-Week High | $96.57 | $9.00 |
52-Week Low | $43.86 | $2.83 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | $3.32B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lemonade (LMND) trades at $43.86, down 2.86% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company continues to show strong revenue growth, with 2025 revenue reaching $738 million and improving margins, though it remains unprofitable with a net loss of $166 million. Recent expansion into Alaska and Kentucky, along with AI-driven efficiency improvements, supports the company's path toward EBITDA profitability by late 2026.
While Lemonade shows promising growth and margin improvement, the stock faces near-term technical pressure and persistent profitability challenges. The consensus price target of $67 offers significant upside potential, but investors must weigh expansion opportunities against ongoing losses and competitive pressures in the insurtech space.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
